A 23-year-old male started using Redensyl and Aminexil, along with Tab BTN Ultra and Vitamin D3 supplements, for hair loss. He shared progress pictures after 45-50 days of treatment.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.
The conversation discusses using minoxidil for hair loss, with one person restarting treatment and combining it with tretinoin, and another person seeing improvement by adding microneedling.
A 17-year-old improved his hairline using minoxidil and derma stamping, planning to start finasteride at 18. He received advice on dosing and potential side effects to maintain results.
A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.
The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.
RU58841 is generally considered ineffective as a standalone hair loss treatment, with most users combining it with finasteride or dutasteride for better results. Few report success using RU58841 alone.
The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.
Switching from finasteride to dutasteride led to hair loss despite continued use of minoxidil. Many recommend reintroducing finasteride, as responses to treatments can vary.
The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.
The user experienced hair regrowth using finasteride and topical minoxidil, with consistent application and lifestyle changes like using cold water and exercising. They noted initial shedding when restarting minoxidil but saw positive results over six months.
A user shared their hair regrowth progress after a year of derma stamping, daily minoxidil, and four months of oral finasteride, along with regular workouts. Others discussed the effectiveness of these treatments and additional methods like red light therapy and RU58841.
The user is considering switching from finasteride and RU58841 to dutasteride due to ongoing hair loss concerns. They are unsure if the hair loss is due to shedding or worsening condition.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The conversation is about the long-term use of RU58841 for hair loss, with users sharing their experiences and seeking information on its effectiveness and whether it needs to be used continuously like minoxidil or finasteride.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The user has been using oral minoxidil and finasteride but continues to experience hair thinning. They are considering adding RU58841 or dutasteride to their regimen for better results.
RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
A 29-year-old shares progress on hair recovery using a daily liposomal topical mix of finasteride and minoxidil, iRestore device, and several vitamins. They report no side effects from the topical treatment, unlike previous issues with oral finasteride.
The individual has been using minoxidil for beard growth for over two years, started oral minoxidil and dutasteride six months ago, and began RU58841 three months ago, which significantly enhanced their results. They are open to answering questions about their hair loss treatment experience.